ვიკიპედია

COVID-19-ის ვაქცინა: განსხვავება გადახედვებს შორის

ისტორიის ინტერაქციულად გადახედვა
[შემოწმებული ვერსია][შემოწმებული ვერსია]
← წინა ცვლილებაშემდეგი ცვლილება →
შიგთავსი ამოიშალა შიგთავსი დაემატა
ვიზუალურივიკიტექსტი
ხაზი 151:
 
ცდების პროცესში დაგროვებული ინდიკატორების მიხედვით, კლინიკური ცდების მეთოდიკა შეიძლება შეიცვალოს და ადაპტირდეს მკურნალობის ნეგატიური და პოზიტიური შედეგებიდან გამომდინარე.<ref name="pallmann">{{cite journal | vauthors = Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JM, Weir CJ, Wheeler GM, Yap C, Jaki T | display-authors = 6 | title = Adaptive designs in clinical trials: why use them, and how to run and report them | journal = BMC Medicine | volume = 16 | issue = 1 | pages = 29 | date = February 2018 | pmid = 29490655 | pmc = 5830330 | doi = 10.1186/s12916-018-1017-7 }}</ref><ref name="fda-adaptive">{{#invoke:Cite web| |date=1 November 2019|title=Adaptive designs for clinical trials of drugs and biologics: Guidance for industry|url=https://www.fda.gov/media/78495/download|archive-url=https://web.archive.org/web/20191213234438/https://www.fda.gov/media/78495/download|archive-date=13 December 2019|url-status=live|access-date=3 April 2020|publisher=U.S. [[Food and Drug Administration]] (FDA)|format=PDF}}</ref> ზოგიერთ შემთხვევაში II–III ფაზების ადაპტირება საშუალებას იძლევა, შემცირდეს ცდების ხანგრძლივობა და საჭირო სუბიექტების რაოდენობა, რაც გამორიცხავს დუბლირებულ და არასაჭირო კვლევებს.ამავე დროს, ხდება ცდების დიზაინში და მეთოდებში შეტანილი ცვლილებების გაზიარება საერთაშორისო მასშტაბით, სხვა ადგილებში მიმდინარე ცდების ადაპტირების მიზნით.<ref name="pallmann" /><ref name="solidarity-vacc2">{{#invoke:Cite web| |date=9 April 2020|title=An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial|url=https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf|archive-url=https://web.archive.org/web/20200512115627/https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf|archive-date=12 May 2020|url-status=live|access-date=9 May 2020|publisher=[[World Health Organization]] (WHO)}}</ref>
 
=== ავტორიზებული და ნებადართული ვაქცინების სია ===
 
ამჟამად, ეროვნული რეგულატორების მიერ გადაუდებელი გამოყენებისათვის ავტორიზებულია 15 ვაქცინა. ამათგან 6 ავტორიზებული გადაუდებელი ან სრული გამოყენებისთვის ჯანმოს მიერ აღიარებული სულ მცირე ერთი მკაცრი რეგულატორის მიერ. Pfizer–BioNTech-ს და Moderna-ს აშშ-ის საკვებისა და წამლის ადმინისტრაციაში თავიანთი ვაქცინებისთვის ბიოლოგიური ლიცენზიის აპლიკაციაც აქვთ შეტანილი, რაც ქვეყნის მასშტაბით ახალი ბიოლოგიური პროდუქტით ვაჭრობის ნებართვას ითვალისწინებს.<ref>{{cite press release | title=Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine | website=Pfizer | date=7 May 2021 | url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-biologics | access-date=9 June 2021}}</ref><ref>{{cite press release | title=Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine | publisher=Moderna | via=Business Wire | date=1 June 2021 | url=https://www.businesswire.com/news/home/20210601005270/en/Moderna-Announces-Initiation-of-Rolling-Submission-of-Biologics-License-Application-BLA-with-U.S.-FDA-for-the-Moderna-COVID-19-Vaccine | access-date=9 June 2021}}</ref>
Line 165 ⟶ 163:
COVID-19 subunit and VLP vaccines authorization map.svg|<div style="text-align:left">სუბიუნიტური ვაქცინები{{Legend|#008888|[[EpiVacCorona]]}}{{Legend|#8C00FF|[[ZF2001]]}}{{Legend|#880000|[[w:Abdala (vaccine)|Abdala]]}}{{Legend|#000088|[[w:Soberana 02|Soberana 02]]}}{{Legend|#FF008C|[[w:MVC-COV1901|Medigen (MVC)]]}}</div>
</gallery>
 
<!-- default sorting: total number of authorizations (emergency + full) -->
{| class="wikitable sortable"
|+გადაუდებელი გამოყენებისთვის ან სრულად ავტორიზებული ვაქცინები
|-
!scope="col"|ვაქცინა, შემქმნელები/სპონსორები
!scope="col"|ქვეყანა
!scope="col"|ტიპი (ტექნოლოგია)
!scope="col"|დოზები, ინტერვალები
!scope="col"|შენახვის ტემპერატურა
!scope="col"|პრემარკეტინგული კვლევები (მონაწილეები)
!scope="col"|პოსტმარკეტინგული კვლევები (მონაწილეები)
!scope="col" style="width:10em;"|ავტორიზაცია
|- valign="top"
|'''Oxford–AstraZeneca COVID-19 vaccine''' <small>(Vaxzevria, Covishield)</small><wbr /><ref>{{#invoke:Cite web| | title=Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca }}</ref>{{efn-la|[[Serum Institute of India]] will be producing the ''ChAdOx1{{nbs}}nCoV-19'' vaccine for India<ref>{{cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|title=AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine|work=The Economic Times|access-date=15 June 2020}}</ref> and other low- and middle-income countries.<ref>{{cite news |title=Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries |url=https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |work=The Financial Express |date=7 August 2020}}</ref>}}{{efn-la|Oxford name: ''ChAdOx1 nCoV-19''. Manufacturing in Brazil to be carried out by [[Oswaldo Cruz Foundation]].<ref>{{cite news | vauthors = Walsh N, Shelley J, Duwe E, Bonnett W |date=27 July 2020 |title=The world's hopes for a coronavirus vaccine may run in these health care workers' veins |url=https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |publisher=CNN |location=São Paulo |access-date=3 August 2020 |name-list-style=vanc |archive-date=3 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200803211040/https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html }}</ref>}}<ref name="NCT04400838">{{#invoke:Cite web| |title=Investigating a Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04400838 |website=[[ClinicalTrials.gov]] |id=NCT04400838 |date=26 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084750/https://clinicaltrials.gov/ct2/show/NCT04400838/ }}</ref><ref name="EudraCT-2020-001228-32">{{#invoke:Cite web| |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |title=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |website=EU Clinical Trials Register |publisher=European Union |id=[[EudraCT]] 2020-001228-32 |date=21 April 2020 |access-date=3 August 2020 |archive-date=5 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201005201654/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB }}</ref><ref name="ISRCTN89951424">{{cite journal |title=A Phase III study to investigate a vaccine against COVID-19 |website=ISRCTN |id=ISRCTN89951424 |doi=10.1186/ISRCTN89951424 |date=26 May 2020 | vauthors = O'Reilly P | doi-access=free }}</ref><br />[[ოქსფორდის უნივერსიტეტი]],[[AstraZeneca]], [[Coalition for Epidemic Preparedness Innovations|CEPI]]
|გაერთიანებული სამეფო, შვედეთი
|ადენოვირუსული ვექტორული ვაქცინა ([[ChAdOx1]])<wbr /><ref name="NCT04400838" />
|2 დოზა<br />4–12 კვირა<wbr /><ref>{{cite news|last1=Gallagher |first1=James |last2=Triggle |first2=Nick |date=30 December 2020 |title=Covid-19: Oxford-AstraZeneca vaccine approved for use in UK |url=https://www.bbc.com/news/health-55280671 |work=[[BBC News Online]] |access-date=5 March 2020| name-list-style = vanc}}</ref>
|2-8°C<wbr /><ref>{{cite techreport |type=Product Monograph |date=26 February 2021 |title=AstraZeneca COVID-19 Vaccine |url=https://www.azcovid-19.com/content/dam/azcovid/pdf/canada/ca-pm-azd1222-en.pdf |publisher=[[AstraZeneca]] |id=244627 |access-date=5 March 2021}}</ref>
|'''ფაზა III''' (30,000 მონაწილე)<br>ინტერვენციული; რენდომიზებული, პლაცებოთი კონტროლირებადი კვლევა ეფეტიანობაზე, უსაფრთხოებასა და იმუნოგენურობაზე.<ref name="NCT04516746">{{#invoke:Cite web| |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020 |archive-date=23 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 }}</ref><br>მთლიანი ეფექტურობა 76% პირველი დოზის, ხოლო 81% მეორე დოზის შემდეგ (ინტერვალი 12 კვირა ან მეტი პირველი დოზიდან).<ref name="AZD1222-efficacy">{{cite journal | vauthors = Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJ, Emary KR, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AV, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DP, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ | display-authors = 6 | title = Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials | journal = Lancet | volume = 397 | issue = 10277 | pages = 881–91 | date = March 2021 | pmid = 33617777 | pmc = 7894131 | doi = 10.1016/S0140-6736(21)00432-3 }}</ref><br>2020 წლის მაისიდან 2021 წლის აგვისტომდე, ბრაზილია (5,000),<ref>{{#invoke:Cite web| |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020 |archive-date=9 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch }}</ref> გაერთიანებული სამეფო, ინდოეთი<ref>{{cite news |title=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |work=mint |date=19 August 2020 }}</ref>
|'''ფაზა III''' (10,000 მონაწილე)<ref name="NCT04760132">{{#invoke:Cite web| |url=https://clinicaltrials.gov/ct2/show/NCT04760132 |title=National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) |date=18 February 2021 |website=[[ClinicalTrials.gov]] |access-date=1 June 2021|last1=Md |first1=Jens D. Lundgren | name-list-style = vanc}}</ref><br>ინტერვენციული, არარენდომიზებული<br>2021 წლის თებერვლიდან 2024 წლის დეკემბრამდე, დანია
|სრული (2),<br>გადაუდებელი (172)
|- valign="top"
|'''Pfizer–BioNTech COVID-19 vaccine'''<small>(Comirnaty)</small><wbr /><ref name="hcreg">{{#invoke:Cite web| |date=9 December 2020|title=Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine|url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00730|access-date=9 December 2020|publisher=Health Canada, Government of Canada}}</ref><ref name="NCT04368728">{{#invoke:Cite web| |title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04368728 |website=[[ClinicalTrials.gov]] |id=NCT04368728 |date=30 April 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/ }}</ref><ref name="EudraCT-2020-001038-36">{{#invoke:Cite web| |title=A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |website=EU Clinical Trials Register |publisher=European Union |id=[[EudraCT]] 2020-001038-36 |date=14 April 2020 |access-date=22 April 2020 |archive-url=https://web.archive.org/web/20200422111024/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |archive-date=22 April 2020 |url-status=live}}</ref><br />[[BioNTech]], [[Pfizer]]
|გერმანია, აშშ
|mRNA ვაქცინა (მოდიფიცირებული რნმ ლიპიდურ ნანონაწილაკებში)<wbr /><ref name="hcreg" />
|2 doses<br />3–4 weeks<wbr /><ref>{{Cite news |date=5 January 2021 |title=WHO recommends two doses of Pfizer COVID-19 vaccine within 21–28 days |work=Reuters |location=Geneva |url=https://www.reuters.com/article/us-health-coronavirus-who/who-recommends-two-doses-of-pfizer-covid-19-vaccine-within-21-28-days-idUSKBN29A25G |access-date=5 March 2021 |vauthors=Farge E, Revill J}}</ref>{{efn-la|name=who-extended-interval-rna-vaccines|Recommended interval. The second dose of the Pfizer–BioNTech and Moderna vaccines can be administered up to six weeks after the first dose to alleviate a shortage of supplies.<ref>{{Cite news |date=8 January 2021 |title=WHO: Amid short supplies, vaccine doses can be 6 weeks apart |work=Associated Press |location=Geneva |url=https://apnews.com/article/immunizations-coronavirus-pandemic-united-nations-bb16e94b0726ca810835b7a78b1f86f6 |access-date=6 March 2021 |vauthors=Keaten J}}</ref><ref>{{Cite news |date=26 January 2021 |title=COVID vaccine: Moderna shots can be 6 weeks apart, WHO says |work=Deutsche Welle |url=https://www.dw.com/en/covid-vaccine-moderna-shots-can-be-6-weeks-apart-who-says/a-56348264 |access-date=6 March 2021}}</ref>}}
| data-sort-value="-70" {{shade|align=left|valign=top|color=blue|max=70|70|{{val|-70|10|u=degC}}<wbr />{{efn-la|Long-term storage temperature. The Pfizer–BioNTech COVID-19 vaccine can be kept between {{Convert|-25|and|-15|C|F|abbr=}} for up to two weeks before use, and between {{Convert|2|and|8|C|F|abbr=}} for up to five days before use.<ref>{{Cite press release |title=Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer–BioNTech COVID-19 Vaccine |date=25 February 2021 |publisher=[[Food and Drug Administration]] (FDA) |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer |access-date=5 March 2021}}</ref><ref name="Pfizer–BioNTech COVID-19 Vaccine EUA fact sheet">{{#invoke:Cite web| | title=Pfizer–BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers | publisher=Pfizer | date=25 February 2021 | access-date=25 February 2021 | url=https://www.fda.gov/media/144413/download | format=PDF}}</ref>}}<br />([[ULT freezer|ULT]])}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=43998|description=Randomized, placebo-controlled.
|status=Positive results from an interim analysis were announced on 18 November 2020<ref>{{Cite press release |title=Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints |date=18 November 2020 |publisher=Pfizer |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine}}</ref> and published on 10 December 2020 reporting an overall efficacy of 95%.<ref name="BNT162b2 Vaccine">{{Cite journal |display-authors=6 |vauthors=Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC |date=December 2020 |title=Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine |journal=The New England Journal of Medicine |volume=383 |issue=27 |pages=2603–15 |doi=10.1056/NEJMoa2034577 |pmc=7745181 |pmid=33301246 |doi-access=free}}</ref><ref>{{Cite report |url=https://www.fda.gov/media/144337/download |title=FDA Review of Efficacy and Safety of Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Request |date=10 December 2020 |access-date=11 December 2020 |format=PDF |website=U.S. [[Food and Drug Administration]] (FDA)}} {{PD-notice}}</ref>
|whenwhere=Jul–Nov 2020,<ref>{{Cite news |name-list-style=vanc |date=18 November 2020 |title=Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization |publisher=Reuters |url=https://www.reuters.com/article/health-coronavirus-vaccines-pfizer/pfizer-ends-covid-19-trial-with-95-efficacy-to-seek-emergency-use-authorization-idUSL4N2HZ3VS |access-date=18 November 2020 |vauthors=Erman M}}</ref><ref name="NYT-20201120" /> Germany, United States
}}
|{{ClinicalStudyInfo |phase=4 |participants=10000
|references=<ref name="NCT04760132" />
|description=Interventional, non-randomized
|whenwhere=Feb 2021{{snd}}Dec 2024, Denmark}}
|{{CovidVacNum|Pfizer-BioNTech}}
|- valign="top"
|'''[[Moderna COVID-19 vaccine]]''' <small>(Spikevax)</small><wbr /><ref name="NCT04470427">{{#invoke:Cite web| |title=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427 |website=[[ClinicalTrials.gov]] |id=NCT04470427 |date=14 July 2020 |access-date=27 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084833/https://clinicaltrials.gov/ct2/show/NCT04470427/ }}</ref><ref name="palca">{{cite news | vauthors = Palca J |title=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |access-date=27 July 2020 |publisher=NPR |date=27 July 2020 |name-list-style=vanc |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084836/https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people/ }}</ref><br />[[Moderna]], [[National Institute of Allergy and Infectious Diseases|NIAID]], [[Biomedical Advanced Research and Development Authority|BARDA]], [[Coalition for Epidemic Preparedness Innovations|CEPI]]
|United States
|[[RNA vaccine|RNA]] ([[modRNA]] in [[lipid nanoparticle]]s)<wbr /><ref name="NCT04283461">{{#invoke:Cite web| |title=Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04283461 |website=[[ClinicalTrials.gov]] |id=NCT04283461 |date=16 March 2020 |access-date=5 March 2021}}</ref>
|2 doses<br />4 weeks<wbr /><ref>{{cite news |date=26 January 2021 |title=WHO experts issue recommendations on Moderna COVID-19 vaccine |url=https://www.reuters.com/article/health-coronavirus-who-moderna-idUSL8N2K131U |work=Reuters |location=Geneva |access-date=5 March 2021}}</ref>{{efn-la|name=who-extended-interval-rna-vaccines}}
| data-sort-value="-20" {{shade|align=left|valign=top|color=blue|max=70|20|{{val|-20|5|u=degC}}<wbr /><ref>{{#invoke:Cite web ||type=Fact sheet |url=https://www.fda.gov/media/144637/download | format=PDF |title=Fact Sheet for Healthcare Providers Administering Vaccine |publisher=U.S. [[Food and Drug Administration]] (FDA) |date=December 2020 |access-date=5 March 2021}}</ref><br />([[Refrigerator#Freezer|freezer]])}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.
|status=Positive results from an interim analysis were announced on 15 November 2020<ref>{{#invoke:Cite web| |title=Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine |website=National Institutes of Health (NIH) |date=15 November 2020}}</ref> and published on 30 December 2020 reporting an overall efficacy of 94%.<ref name="mRNA1273 Vaccine">{{cite journal | vauthors = Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T | display-authors = 6 | title = Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | journal = The New England Journal of Medicine | volume = 384 | issue = 5 | pages = 403–16 | date = February 2021 | pmid = 33378609 | pmc = 7787219 | doi = 10.1056/NEJMoa2035389 | doi-access = free }}</ref>
|whenwhere=Jul 2020{{snd}}Oct 2022, United States
}}
|{{ClinicalStudyInfo |phase=4 |participants=10000
|references=<ref name="NCT04760132"/>
|description=Interventional, non-randomized
|whenwhere=Feb 2021{{snd}}Dec 2024, Denmark}}
|{{CovidVacNum|Moderna}}
|- valign="top"
|'''[[Janssen COVID-19 vaccine]]'''<ref name=":2">{{#invoke:Cite web| |title=A Study of Ad26.COV2.S in Adults|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date=23 August 2020|date=4 August 2020|archive-date=16 September 2020|url-status=live|archive-url=https://web.archive.org/web/20200916063346/https://clinicaltrials.gov/ct2/show/NCT04436276}}</ref><ref name=":3">{{#invoke:Cite web| |title=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants|url=https://clinicaltrials.gov/ct2/show/NCT04505722|archive-url=https://web.archive.org/web/20200926145744/https://clinicaltrials.gov/ct2/show/NCT04505722|archive-date=26 September 2020|url-status=live|publisher=US National Library of Medicine}}</ref><br />[[Janssen Vaccines]] ([[Johnson & Johnson]]), [[Beth Israel Deaconess Medical Center|BIDMC]]
|United States, Netherlands
|[[Adenoviridae|Adenovirus]] [[Viral vector vaccine|vector]] ([[Recombinant vaccine|recombinant]] Ad26)<wbr /><ref>{{cite techreport |type=Briefing |date=26 February 2021 |title=Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 |publisher=U.S. [[Food and Drug Administration]] (FDA) |url=https://www.fda.gov/media/146217/download |page=6 |access-date=6 March 2021 |quote=The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilized variant of the SARS-CoV-2 S protein.}}</ref>
|{{good|style=vertical-align:top;text-align=left|1 dose<ref name="nature-jnj">{{cite journal | vauthors = Ledford H | title = J&J's one-shot COVID vaccine offers hope for faster protection | journal = Nature | date = January 2021 | pmid = 33526898 | doi = 10.1038/d41586-021-00119-7 | name-list-style = vanc | doi-access = free }}</ref>}}
| data-sort-value="5" |{{val|2|-|8|u=degC}}<ref name="nature-jnj"/>
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=Randomized, double-blinded, placebo-controlled
|status= Positive results from an interim analysis were announced on 29 January 2021. J&J reports an efficacy of 66% against mild and moderate symptoms, and 85% against severe symptoms. Further, the mild and moderate efficacy ranged from 64% in South Africa to 72% in the United States.<ref>{{cite press release|title=Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial|url=https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial|access-date=29 January 2021|publisher=Johnson & Johnson|date=29 January 2021}}</ref><ref name="Janssen COVID-19 Vaccine FDA label"/>
|whenwhere=Jul 2020{{snd}}? 2023, United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru, the Philippines, South Africa, Ukraine
}}
|
|{{CovidVacNum|Janssen}}
|- valign="top"
|'''[[BBIBP-CorV]]'''<wbr /><ref name="ChiCTR2000034780">{{cite journal | vauthors = Chen W, Al Kaabi N |title=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |journal=Chinese Clinical Trial Registry |date=18 July 2020 |url=http://www.chictr.org.cn/showprojen.aspx?proj=56651 |access-date=15 August 2020 |name-list-style=vanc }}</ref><br />[[China National Pharmaceutical Group|Sinopharm]]: Beijing Institute of Biological Products
|China
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] ([[vero cell]]s)<wbr /><ref name="ChiCTR2000034780" />
|2 doses<br />3–4 weeks<wbr /><ref>{{cite journal | vauthors = Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X | display-authors = 6 | title = Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial | journal = The Lancet. Infectious Diseases | volume = 21 | issue = 1 | pages = 39–51 | date = January 2021 | pmid = 33069281 | pmc = 7561304 | doi = 10.1016/S1473-3099(20)30831-8 | title-link = doi | doi-access = free }}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref>{{cite news | vauthors = Elbahrawy F, Lyu D, Omar A, Che C, Paton J |date=9 December 2020 |title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says |url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19 |work=Bloomberg News |location= |quote=CNBG's vaccine can be transported and stored at normal refrigerated temperatures. |access-date=5 March 2020}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=48000|description=Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy.
|status=Peer-reviewed results indicate 78.1% efficacy against symptomatic COVID-19.<ref name="jama.2021.8565" />
|whenwhere=Jul 2020{{snd}}Jul 2021, United Arab Emirates, Bahrain, Jordan,<ref>{{#invoke:Cite web| | vauthors = Yang Y |title=A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04510207 |access-date=15 September 2020 |name-list-style=vanc |archive-date=14 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200914040138/https://clinicaltrials.gov/ct2/show/NCT04510207 }}</ref> Argentina,<ref>{{#invoke:Cite web| |title=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04560881?term=vaccine&cond=covid-19&draw=2&rank=3 |access-date=28 September 2020 }}</ref> Morocco,<ref>{{#invoke:Cite web| |title=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |url=http://www.chictr.org.cn/showprojen.aspx?proj=62581 |website=Chinese Clinical Trial Register (ChiCTR) |access-date=15 December 2020}}</ref> Peru<ref>{{#invoke:Cite web| |title=Bahrain announces emergency approval for use of COVID-19 vaccine candidate | url=https://www.reuters.com/article/health-coronavirus-bahrain-idUSS8N2GL00I | date=3 November 2020 | access-date=3 November 2020|website=Reuters }}</ref>
}}
|
|{{CovidVacNum|Sinopharm-BBIBP}}
|- valign="top"
|'''[[Sputnik V COVID-19 vaccine]]''' <small>(Gam-COVID-Vac)</small><br />[[Gamaleya Research Institute of Epidemiology and Microbiology]]
|Russia
|[[Adenoviridae|Adenovirus]] [[Viral vector vaccine|vector]] ([[Recombinant vaccine|recombinant]] Ad5 and Ad26)<wbr /><ref name="NCT04436471">{{#invoke:Cite web| |title=An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04436471 |website=[[ClinicalTrials.gov]] |id=NCT04436471 |date=17 June 2020 |access-date=5 March 2021}}</ref>
|2 doses<br />3 weeks<wbr /><ref>{{cite journal | vauthors = Jones I, Roy P | title = Sputnik V COVID-19 vaccine candidate appears safe and effective | journal = Lancet | volume = 397 | issue = 10275 | pages = 642–43 | date = February 2021 | pmid = 33545098 | pmc = 7906719 | doi = 10.1016/S0140-6736(21)00191-4 | title-link = doi | doi-access = free }}</ref>
| data-sort-value="-18" {{shade|align=left|valign=top|color=blue|max=70|18|≤{{val|-18|u=degC}}<wbr />{{efn-la|Storage temperature for the frozen Gam-COVID-Vac formulation. The [[Freeze-drying|lyophilised]] Gam-COVID-Vac-Lyo formulation can be stored at 2-8°C.<ref>{{cite news | vauthors = Sagdiev R, Ivanova P |date=16 November 2020 |title=Russia focuses on freeze-dried vaccine doses as transport fix |url=https://www.reuters.com/article/health-coronavirus-russia-vaccine-transp/rpt-exclusive-russia-focuses-on-freeze-dried-vaccine-doses-as-transport-fix-idUSL1N2I30ML |work=Reuters |location=Moscow |access-date=5 March 2021}}</ref>}}<br />([[Refrigerator#Freezer|freezer]])}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety.<ref>{{#invoke:Cite web| |title=Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST) |url=https://clinicaltrials.gov/ct2/show/NCT04530396 |date=28 August 2020 |id=NCT04530396 |access-date=11 September 2020 |archive-date=14 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200914035126/https://clinicaltrials.gov/ct2/show/NCT04530396 | website=[[ClinicalTrials.gov]] }}</ref>
|status=Interim analysis from the trial was published in ''[[The Lancet]]'', indicating 91.6% efficacy without unusual [[side effect]]s.<ref name="Safety and efficacy of an rAd26 and" />
|whenwhere=Aug 2020{{snd}}May 2021, Russia, Belarus,<ref>{{#invoke:Cite web| |url=https://clinicaltrials.gov/ct2/show/NCT04564716 |title=Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus | website=[[ClinicalTrials.gov]] |date=25 September 2020 |access-date=18 January 2021 |id=NCT04564716}}</ref> India,<ref>{{cite news | vauthors = Kumar S |title=Sputnik-V from Russia arrives in India for clinal trials |url=https://www.hindustantimes.com/india-news/sputnik-v-from-russia-arrives-in-india-for-clinal-trials/story-b8k3Ecncxw2RBTrIxOiqxO.html |work=Hindustan Times |date=1 December 2020 }}</ref><ref>{{cite news |title=Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune |url=https://indianexpress.com/article/india/clinical-trial-17-volunteers-given-russias-sputnik-v-covid-19-vaccine-in-pune-7094153/ |work=The Indian Express |date=6 December 2020 }}</ref> Venezuela,<ref>{{#invoke:Cite web| |url=https://clinicaltrials.gov/ct2/show/NCT04642339 |title=Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela (VENEZUELA)
| website=[[ClinicalTrials.gov]] |date=24 November 2020 |access-date=18 January 2021 |id=NCT04642339}}</ref> United Arab Emirates<ref>{{cite news |title=UAE begins trials of Russia's Sputnik V Covid-19 vaccine |url=https://www.clinicaltrialsarena.com/news/uae-begins-sputnik-v-trial/ |work=Clinical Trials Arena |date=8 January 2021 }}</ref>
}}
|
|{{CovidVacNum|Sputnik V}}
|- valign="top"
|'''[[CoronaVac]]'''<ref name="NCT04383574">{{#invoke:Cite web| |title=Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu) |url=https://clinicaltrials.gov/ct2/show/NCT04383574 |website=[[ClinicalTrials.gov]] |id=NCT04383574 |date=12 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084809/https://clinicaltrials.gov/ct2/show/NCT04383574/ }}</ref><ref name="NCname= nct04456595=">{{#invoke:Cite web| |url=https://clinicaltrials.gov/ct2/show/NCT04456595 |title=Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV) |website=[[ClinicalTrials.gov]] |id=NCT04456595 |date=2 July 2020 |access-date=3 August 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084811/https://clinicaltrials.gov/ct2/show/NCT04456595/ }}</ref><ref name=":1">{{cite journal |last1=PT. Bio Farma |title=A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia |journal=Registri Penyakit Indonesia |date=10 August 2020 |url=https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX |access-date=15 August 2020 | name-list-style = vanc}}</ref><br />[[Sinovac Biotech|Sinovac]]
|China
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] ([[vero cell]]s)<wbr /><ref name="NCT04383574"/>
|2 doses<br />2–4 weeks<wbr /><ref>{{cite news |title=The Sinovac COVID-19 vaccine: What you need to know |url=https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know |access-date=3 July 2021 |publisher=World Health Organization |date=2 June 2021}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref>{{cite news|last=Tan |first=Yvette |date=14 January 2021 |title=Covid: What do we know about China's coronavirus vaccines? |url=https://www.bbc.com/news/world-asia-china-55212787 |work=[[BBC News Online]] |access-date=5 March 2020| name-list-style = vanc}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=33,620|description=Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.|status=Peer-reviewed Phase III results from Turkey showed an efficacy of 83.5%.<ref name="S0140-6736(21)01429-X" /> A Chilean study showed 65% efficacy against symptomatic cases, 87% against hospitalization, 90% against ICU admissions, and 86% against deaths.<ref name=":25" /><ref name=":26">{{cite news|date=17 May 2021|title=Coronavirus en Chile: Reporte Minsal 17 de Mayo|trans-title=Coronavirus in Chile: Minsal report May 17|language=es|url=https://www.youtube.com/watch?v=uHC4XTpwJHU|website=YouTube}}</ref> Brazil announced results showing 50.7% effective at preventing symptomatic infections, 83.7% effective in preventing mild cases, and 100% effective in preventing severe cases.<ref name="CNN Brasil">{{cite news| vauthors = Costa AG |date=11 April 2021|title=Estudo clínico que comprova maior eficácia da Coronavac é enviado para Lancet|language=Portuguese|trans-title=Clinical study proving greater efficacy of Coronavac is submitted to The Lancet|work=CNN Brasil|location=São Paulo|url=https://www.cnnbrasil.com.br/saude/2021/04/11/estudo-clinico-que-comprova-maior-eficacia-da-coronavac-e-enviado-para-lancet|access-date=12 April 2021| name-list-style = vanc}}</ref>|whenwhere=July 2020{{snd}}Oct 2021, Brazil (15,000);<ref>{{#invoke:Cite web| |url=https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils |title=Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute |access-date=29 October 2020 |archive-date=29 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201029151527/https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils }}</ref> Aug 2020{{snd}}January 2021, Indonesia (1,620); Oct{{snd}}Nov 2020, China (1,040);<ref>{{#invoke:Cite web| |title=Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults |url=https://clinicaltrials.gov/ct2/show/NCT04617483 |website=[[ClinicalTrials.gov]] |date=5 November 2020 |access-date=6 June 2021 | id=NCT04617483}}</ref> Nov 2020{{snd}}Jan 2022,<ref>{{#invoke:Cite web| |title=Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL) |url=https://clinicaltrials.gov/ct2/show/NCT04651790 |website=[[ClinicalTrials.gov]] |date=3 December 2020 |access-date=6 June 2021 |id=NCT04651790}}</ref> Chile (3,000);<ref>{{#invoke:Cite web| |url=https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine |title=Chile initiates clinical study for COVID-19 vaccine |access-date=29 October 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011190302/https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine }}</ref> Apr 2021{{snd}}Jun 2022, the Philippines (phase II/III: 352);<ref>{{#invoke:Cite web ||title=A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60–80 Years of Age, Coronovac ENCOV19 Study |url=https://registry.healthresearch.ph/index.php/registry?view=research&layout=details&cid=3308 |website=registry.healthresearch.ph |publisher=Philippine Health Research Registry |access-date=23 April 2021}}</ref> Sep 2020{{snd}}Feb 2021, Turkey (13,000);<ref>{{#invoke:Cite web| |title=Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated |url=https://clinicaltrials.gov/ct2/show/NCT04582344 |date=8 October 2020 |access-date=22 October 2020 |archive-date=20 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201020123218/https://clinicaltrials.gov/ct2/show/NCT04582344 }}</ref>}}
|{{ClinicalStudyInfo |phase=4 |participants=37867
|references=<ref name="NCT04747821">{{cite journal |url=https://clinicaltrials.gov/ct2/show/NCT04747821 |title=An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine (Projeto S) |date=10 February 2021 |website=[[ClinicalTrials.gov]] |access-date=1 June 2021 |id=NCT04747821}}</ref><ref name="NCT04789356">{{cite journal |url=https://clinicaltrials.gov/ct2/show/NCT04789356 |title=Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity (COVACMANAUS) |date=9 March 2021 |website=[[ClinicalTrials.gov]] |access-date=1 June 2021 |id=NCT04789356}}</ref>
|description=Interventional
|whenwhere=Feb 2021{{snd}}Feb 2022, Serrana (São Paulo) (27,711); Mar 2021{{snd}}Mar 2022, Manaus (10,156)}}
|{{CovidVacNum|CoronaVac}}
|- valign="top"
|'''[[Covaxin]]'''<br />[[Bharat Biotech]], [[Indian Council of Medical Research]]
|India
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] ([[vero cell]]s)<wbr /><ref>{{#invoke:Cite web| |title=Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152) |url=https://clinicaltrials.gov/ct2/show/NCT04471519 |id=NCT04471519 |date=15 July 2020 |website=[[ClinicalTrials.gov]]}}</ref>
|2 doses<br />4 weeks<wbr /><ref name="bbc-covaxin">{{cite news |date=16 June 2021 |title=Covovax, Biological E: What we know about India's new Covid-19 vaccines |url=https://www.bbc.com/news/world-asia-india-55748124 |work=[[BBC News Online]] |quote="The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C." |access-date=19 June 2021}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref name="bbc-covaxin" />
|{{ClinicalStudyInfo|align=left|phase=3|participants=25800|description=Randomised, observer-blinded, placebo-controlled<ref>{{#invoke:Cite web| |title=An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers |id=NCT04641481| url=https://clinicaltrials.gov/ct2/show/NCT04641481|access-date=26 November 2020 |date=23 November 2020 |website=[[ClinicalTrials.gov]]}}</ref>
|status= Bharat Biotech reported an interim efficacy is 78% for its phase 3 trial.<ref>{{Cite news|last=Koshy|first=Jacob|date=21 April 2021|title=Updated data from Covaxin phase 3 trial shows 78% efficacy|work=The Hindu|url=https://www.thehindu.com/sci-tech/health/updated-data-from-covaxin-phase-3-trial-shows-78-efficacy/article34376018.ece|access-date=24 April 2021|issn=0971-751X| name-list-style = vanc}}</ref>
|whenwhere=Nov 2020{{snd}}Mar 2021, India.
}}
|{{ClinicalStudyInfo |phase=4 |participants=1000
|references=<ref name="CTRI/2021/01/030782">{{#invoke:Cite web| | website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]| title=A prospective, longitudinal, observational, post licensure vaccine evaluation study to assess the effectiveness of COVID-19 vaccine among the Healthcare workers of Max group of hospitals |id=CTRI/2021/01/030782 |url=http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=52014| date=24 June 2021|access-date=3 July 2021|first1=Sujeet|last1=Jha| name-list-style = vanc}}</ref>
|description=Interventional, non-randomized
|whenwhere=July 2021{{snd}}Dec 2021, India}}
|{{CovidVacNum|Covaxin}}
|- valign="top"
|'''[[Sputnik Light]]''' <br />[[Gamaleya Research Institute of Epidemiology and Microbiology]]<ref>{{cite news |title=Russia Approves Single-Dose Sputnik Light Covid Vaccine For Use |url=https://www.ndtv.com/world-news/russia-approves-single-dose-sputnik-light-covid-19-vaccine-for-use-2436470 |publisher=NDTV Coronavirus |date=6 May 2021}}</ref>
|Russia
|[[Adenoviridae|Adenovirus]] [[Viral vector vaccine|vector]] ([[Recombinant vaccine|recombinant]] Ad26)<ref name="NCT04741061"/>
|{{good|style=vertical-align:top;text-align=left|1 dose}}<ref name="NCT04741061"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<ref>{{cite press release |date=6 May 2021 |title=Single dose vaccine, Sputnik Light, authorized for use in Russia |url=https://rdif.ru/Eng_fullNews/6763/ |publisher=Russian Direct Investment Fund |access-date=7 May 2021}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=7000|references=<ref>{{cite news |author1=Leo, Leory |title=Russia OKs single-dose Sputnik Light vaccine |url=https://www.livemint.com/companies/news/russia-gives-authorisation-to-single-dose-sputnik-light-vaccine-11620315019710.html |publisher=Mint |date=7 May 2021}}</ref>
|description=Randomised, double-blind, placebo-controlled trial<ref name="NCT04741061">{{#invoke:Cite web| |title=Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (SPUTNIK-LIGHT) |url=https://clinicaltrials.gov/ct2/show/NCT04741061 }}</ref>
|whenwhere=Feb {{snd}}Dec 2021, Russia (6,000)
}}
|
|{{CovidVacNum|Sputnik Light}}
|- valign="top"
|'''[[Convidecia]]'''<br />[[CanSino Biologics]], Beijing Institute of Biotechnology of the [[Academy of Military Medical Sciences]]
|China
|[[Adenoviridae|Adenovirus]] [[Viral vector vaccine|vector]] ([[Recombinant vaccine|recombinant]] Ad5)<wbr /><ref name="zhu7-20">{{cite journal | vauthors = Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W | display-authors = 6 | title = Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial | journal = Lancet | volume = 396 | issue = 10249 | pages = 479–88 | date = August 2020 | pmid = 32702299 | pmc = 7836858 | doi = 10.1016/s0140-6736(20)31605-6 | lay-url = https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-cansino-vaccine | title-link = doi | doi-access = free }}</ref>
|{{good|style=vertical-align:top;text-align=left|1 dose<ref name="reuters-convidecia">{{cite news | vauthors = Peshimam G, Farooq U |date=8 February 2021 |title=CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-657-effective-in-global-trials-pakistan-official-says-idUSKBN2A81N0 |work=Reuters |location=Islamabad |quote=its single-dose regimen and normal refrigerator storage requirement could make it a favourable option for many countries |access-date=5 March 2021}}</ref>}}
| data-sort-value="5" |{{val|2|-|8|u=degC}}<ref name="reuters-convidecia" />
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=Global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity.
|status=In February 2021, interim analysis from global trials showed an efficacy of 65.7% against symptomatic cases of COVID-19 and 90.98% efficacy against severe cases.<ref name="reuters-convidecia"/>|whenwhere=Mar–Dec 2020, China; Sep 2020{{snd}}Dec 2021, Pakistan; Sep–Nov 2020, Russia,<ref name="NCT04540419">{{#invoke:Cite web| |title=Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04540419 |website=[[ClinicalTrials.gov]] |id=NCT04540419 |date=13 November 2020 |access-date=17 November 2020}}</ref> China, Argentina, Chile;<ref>{{#invoke:Cite web| | vauthors = Lazcano P |title=Así funcionan las cuatro vacunas que se probarán en Chile |url=https://www.latercera.com/que-pasa/noticia/asi-funcionan-las-cuatro-vacunas-que-se-probaran-en-chile/AD22DRDA4REH5MRWGIAI7GQFSM/ |publisher=La Tercera |access-date=15 December 2020 |date=15 November 2020|name-list-style=vanc}}</ref> Mexico;<ref>{{cite news | vauthors = Martinez AI | title=CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial |url=https://www.reuters.com/article/idUSKBN27J21V |publisher=Reuters |access-date=4 November 2020 |date=3 November 2020|name-list-style=vanc}}</ref> Pakistan;<ref>{{#invoke:Cite web| | vauthors = Ng E |title=China's CanSino trials Covid-19 vaccine in 'high disease burden' nations |url=https://www.scmp.com/business/companies/article/3107389/chinese-vaccine-developer-cansino-targets-high-disease-burden |work=South China Morning Post |access-date=4 November 2020 |date=28 October 2020|name-list-style=vanc}}</ref> Saudi Arabia<ref>{{cite news | vauthors = Nafisa E |title=CanSino to start Phase III trial of COVID-19 vaccine in Saudi |url=https://www.reuters.com/article/us-health-coronavirus-saudi-cansinobio/cansino-to-start-phase-iii-trial-of-covid-19-vaccine-in-saudi-idUSKCN2550L9 |publisher=Reuters |access-date=4 November 2020 |date=9 August 2020|name-list-style=vanc}}</ref><ref>{{#invoke:Cite web| | vauthors = Gou J |title=Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04526990 |access-date=17 September 2020 |name-list-style=vanc |archive-date=18 September 2020 |url-status=live|archive-url=https://web.archive.org/web/20200918142722/https://clinicaltrials.gov/ct2/show/NCT04526990 }}</ref>}}
|
|{{CovidVacNum|Convidecia}}
|- valign="top"
|'''[[WIBP-CorV]]'''<br />[[Sinopharm]]: Wuhan Institute of Biological Products
|China
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] ([[vero cells]])
|2 doses<br />3 weeks<wbr /><ref name="NCT04510207"/><ref name="NCT04612972"/><ref name="wibp-efficacy-doses">{{cite news |date=25 February 2021 |title=Two Chinese-developed COVID-19 vaccines under review |url=http://english.nmpa.gov.cn/2021-02/25/c_596752.htm |publisher=National Medical Products Administration |access-date=11 April 2021}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=51,600
|description=Randomized, double-blind, placebo-controlled<ref name="sinopharmwuhan">{{cite journal | vauthors = Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X | display-authors = 6 | title = Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials | journal = JAMA | volume = 324 | issue = 10 | pages = 951–960 | date = September 2020 | pmid = 32789505 | pmc = 7426884 | doi = 10.1001/jama.2020.15543 | name-list-style = vanc }}</ref>
|status=Peer-reviewed results indicate 72.8% efficacy against symptomatic COVID-19.<ref name="jama.2021.8565" />
|whenwhere=Jul 2020{{snd}}Mar 2021, Bahrain, Egypt, Jordan, United Arab Emirates;<ref name="NCT04510207">{{Cite journal|last=China National Biotec Group Company Limited|date=29 October 2020|others=G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd.|title=Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above|url=https://clinicaltrials.gov/ct2/show/NCT04510207|website=[[ClinicalTrials.gov]]| name-list-style = vanc}}</ref> Sep 2020{{snd}}Sep 2021, Peru;<ref name="NCT04612972">{{Cite journal|last=Universidad Peruana Cayetano Heredia|date=3 November 2020|others=National University of San Marcos, Peru|title=Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru)|url=https://clinicaltrials.gov/ct2/show/NCT04612972|website=[[ClinicalTrials.gov]] |id=NCT04612972| name-list-style = vanc}}</ref> Sep 2020{{snd}}Dec 2020, Morocco<ref name="ChiCTR2000039000">{{#invoke:Cite web||title=Chinese Clinical Trial Register (ChiCTR) – The world health organization international clinical trials registered organization registered platform|url=http://www.chictr.org.cn/showprojen.aspx?proj=62581|access-date=1 April 2021|website=www.chictr.org.cn}}</ref> }}
|
|{{CovidVacNum|Sinopharm-WIBP}}
|- valign="top"
|'''[[EpiVacCorona]]'''<wbr /><ref name="RJII-11-2">{{cite journal | vauthors = Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Danilenko ED, Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov SA, Tregubchak TV, Antonec DV, Gavrilova EV, Maksyutov RA | display-authors=6 | title = A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (Phase I–II). | journal = Russian Journal of Infection and Immunity | volume = 11 | issue = 2 | pages = 283–96 | date = 2021 | doi = 10.15789/2220-7619-ASB-1699 | url = https://www.iimmun.ru/iimm/article/view/1699 | doi-access = free }}</ref><ref name="vestnikramn1">{{cite journal | vauthors = Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Danilenko ED, Imatdinov IR,Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov SA, Tregubchak TV, Antonec DV, Sleptsova ES, Gavrilova EV, Maksyutov RA | display-authors=6 | title = Immunogenicity and Protectivityof the Peptide Vaccine againstSARS-CoV-2 | journal = Annals of the Russian Academy of Medical Sciences | volume = 76 | issue = 1 | pages = 5–19 | date = 2021 | doi = 10.15690/vramn1528 | url = https://vestnikramn.spr-journal.ru/jour/article/view/1528| doi-access = free }}</ref><br />[[State Research Center of Virology and Biotechnology VECTOR|Vector Institute]]
|Russia
|[[Subunit vaccine|Subunit]] ([[Peptide vaccine|peptide]])<wbr /><ref name="RJII-11-2" />
|2 doses<br />3 weeks<wbr /><ref name="RJII-11-2" />
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref>{{cite report |type=Bulletin | vauthors = Benedyczak J |date=12 February 2021 |title=Russia's Problems in the Vaccine Race |url=https://pism.pl/publications/Russias_Problems_in_the_Vaccine_Race |publisher=[[Polish Institute of International Affairs]] |access-date=6 March 2021 |quote=the Sputnik V and EpiVacCorona can be transported and stored at temperatures of +2 to + 8° C}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,150(planned), 3000(started)|references=<ref>{{#invoke:Cite web ||date=14 October 2020 |title=О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора "ЭпиВакКорона" |trans-title=On the registration of the vaccine FBSI SSC VB "Vector" Rospotrebnadzor "EpiVacCorona" |url=https://www.rospotrebnadzor.ru/region/rss/rss.php?ELEMENT_ID=15660 |access-date=12 May 2021 |language=RU|quote=Запланированы два пострегистрационных клинических исследования: клиническое исследование с участием 150 человек старше 60 лет и многоцентровое клиническое исследование с участием 40 000 добровольцев. |trans-quote=Two post-marketing clinical trials are planned: a clinical trial involving 150 people over 60 years of age and a multicenter clinical trial involving 40,000 volunteers. |publisher=[[Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing]] |website=rospotrebnadzor.ru}}</ref>|description=Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety
|whenwhere=Nov 2020{{snd}}Dec 2021, Russia (3,000)<ref>{{cite news |title=Russian EpiVacCorona Vaccine Has No Adverse Effects |url=https://www.oreanda.ru/en/gosudarstvo/russian-epivaccorona-vaccine-has-no-adverse-effects/article1354486/ |work=Oreanda News |date=13 January 2021 }}</ref><ref>{{cite web |author1=Center of Virology and Biotechnology "Vector" |title=Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04780035 |access-date=12 May 2021 |date=2 March 2021}}</ref><ref>{{#invoke:Cite web||url=https://meduza.io/en/feature/2021/03/27/sputnik-v-s-ugly-cousin |title=Sputnik V's ugly cousin |date=27 March 2021 |website=[[Meduza]] |access-date=12 May 2021}}</ref><ref>{{#invoke:Cite web||url=https://www.reuters.com/article/us-health-coronavirus-russia-vaccine-let-idUSKBN2BI25B |title=Volunteers break rank to raise doubts in trial of Russia's second COVID-19 vaccine |date=26 March 2021 |website=[[Reuters]] |access-date=12 May 2021}}</ref>
}}
|
|{{CovidVacNum|EpiVacCorona}}
|- valign="top"
|'''[[ZF2001]]''' <small>(ZIFIVAX)</small><ref name="london" /><br />Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.
|China
|[[Subunit vaccine|Subunit]] ([[Recombinant vaccine|recombinant]])
|3 doses<br />30 days<wbr /><ref name="NCT04646590" /><ref>{{cite news |date=23 December 2020 |title=China's CAS COVID-19 vaccine induces immune response in mid-stage tests |url=https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN28X0RW |work=Reuters |location=Beijing |access-date=8 March 2021}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref>{{cite journal | vauthors = Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Gao L, Gao GF | display-authors = 6 | title = Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials | journal = The Lancet. Infectious Diseases | date = March 2021 | volume = 21 | issue = 8 | pages = 1107–1119 | pmid = 33773111 | pmc = 7990482 | doi = 10.1016/S1473-3099(21)00127-4 | doi-access = free }}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=29,000
|description=Randomized, double-blind, placebo-controlled<ref name="NCT04646590">{{#invoke:Cite web| |title=A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04646590#wrapper }}</ref>
|whenwhere=Dec 2020{{snd}}Apr 2022, China, Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan<ref>{{#invoke:Cite web| | vauthors = Pinghui Z |title=Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials |url=https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3 |work=South China Morning Post |access-date=26 December 2020 |date=20 November 2020| name-list-style=vanc}}</ref><ref>{{#invoke:Cite web| | vauthors = Ying TP |title=MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia |url=https://www.nst.com.my/news/nation/2020/12/647456/myeg-conduct-phase-3-clinical-trial-chinas-covid-19-vaccine-msia |work=New Straits Times |access-date=28 December 2020 |date=7 December 2020| name-list-style=vanc}}</ref>}}
|
|{{CovidVacNum|Zifivax}}
|- valign="top"
|'''[[Abdala (vaccine)|Abdala]]'''<br />[[BioCubaFarma]], [[:es:Centro de Ingeniería Genética y Biotecnología de Cuba|Center for Genetic Engineering and Biotechnology]]
|Cuba
|[[Subunit vaccine|Subunit]]
|3 doses<br />2 weeks<wbr /><ref name="RPCEC00000359"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref name="soberana-abdala-storage-temperature">{{cite news |last1=Faiola |first1=Anthony |last2=Herrero |first2=Ana Vanessa |title=Against the odds, Cuba could become a coronavirus vaccine powerhouse |url=https://www.washingtonpost.com/world/2021/03/29/cuba-coronavirus-vaccine-iran-venezuela/ |access-date=2 July 2021 |work=The Washington Post |date=29 March 2021 |quote=Cuban officials say they’re developing cheap and easy-to-store serums. They are able to last at room temperature for weeks, and in long-term storage as high as 46.4 degrees}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=48290|references=<ref>{{cite news |title=Cuba says its Abdala vaccine among the most effective in the world |url=https://www.financialexpress.com/lifestyle/health/cuba-says-its-abdala-vaccine-among-the-most-effective-in-the-world/2277680/ |access-date=2 July 2021 |publisher=Financial Express |date=24 June 2021}}</ref>|description=Multicenter, randomized, double-blind, placebo-controlled.<ref name="RPCEC00000359">{{#invoke:Cite web| |title=ABDALA Clinical Study – Phase III |url=https://rpcec.sld.cu/en/trials/RPCEC00000359-En |website=rpcec.sld.cu |publisher=Registro Público Cubano de Ensayos Clínicos |access-date=22 March 2021 }}</ref>
|whenwhere=Mar–Jul 2021, Cuba
}}
|
|{{CovidVacNum|Abdala}}
|- valign="top"
|'''[[CoviVac (Russia COVID-19 vaccine)|CoviVac]]'''<ref>{{#invoke:Cite web| |url=http://government.ru/en/news/41342/|title=Briefing with Deputy Prime Minister Tatyana Golikova, Health Minister Mikhail Murashko and Head of Rospotrebnadzor Anna Popova |publisher=Government of Russia |date=18 January 2021 |access-date=20 February 2021}}</ref><br />The Chumakov Centre at the [[Russian Academy of Sciences]]
|Russia
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] ([[vero cells]])<wbr /><ref>{{cite news | vauthors = Ryumin A |date=20 February 2021 |title=Russia registers its third COVID-19 vaccine CoviVac |url=https://tass.com/society/1258859 |work=[[TASS]] |location=Moscow |access-date=6 March 2021}}</ref>
|2 doses<br />2 weeks<wbr /><ref name="reuters-covivac">{{cite news | vauthors = Ivanova P |date=8 February 2021 |title=Russia approves its third COVID-19 vaccine, CoviVac |url=https://www.reuters.com/article/us-health-coronavirus-russia-vaccine-idUSKBN2AK07H |work=Reuters |location=Moscow |quote='The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2{{nbs}}to 8{{nbs}}degrees Celsius (35.6 to 46.4 Fahrenheit),' Deputy Prime Minister Tatiana Golikova said in a government briefing in January. |access-date=5 March 2021}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref name="reuters-covivac"/>
|{{ClinicalStudyInfo|align=left|phase=3|participants=32,000|references=<ref>{{Cite news|title=Центр Чумакова обнародовал сроки третьей фазы испытаний вакцины против COVID-19 |url=https://govoritmoskva.ru/news/270851/|access-date=19 April 2021|website=govoritmoskva.ru |language=ru |trans-title=Chumakov Center announced the timing of the third phase of trials of the vaccine against COVID-19 |date=19 April 2021}}</ref>|description=Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.|whenwhere=May 2021{{snd}}?, Russia (3,000)<ref>{{cite news |author1=AFP |title=Russia registers third COVID-19 vaccine |url=https://www.timesofisrael.com/russia-registers-third-covid-19-vaccine/ |publisher=The Times of Israel |date=20 February 2021}}</ref>
}}
|
|{{CovidVacNum|CoviVac}}
|- valign="top"
|'''[[QazCovid-in]]''' <small>(QazVac)</small><ref>{{#invoke:Cite web| | vauthors = Yergaliyeva A |title=Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in |url=https://astanatimes.com/2020/12/kazakhstan-begins-vaccinating-3000-volunteers-with-self-made-qazcovid-in/ |website=The Astana Times |access-date=2 March 2021 |date=20 December 2020}}</ref><br />Research Institute for Biological Safety Problems
|Kazakhstan
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]]
|2 doses<br />3 weeks<wbr /><ref>{{#invoke:Cite web| |last1=Meyer |first1=David |title=A new vaccine on the scene: Kazakhstan begins rollout of homegrown QazVac |url=https://fortune.com/2021/04/26/new-covid-19-vaccine-kazakhstan-qazvac/ |website=Fortune |access-date=26 April 2021 |date=26 April 2021| name-list-style = vanc}}</ref>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref>{{#invoke:Cite web| |last1=Gotev |first1=Georgi |title=Kazakhstan launches QazVac, its own COVID-19 vaccine |url=https://www.euractiv.com/section/central-asia/news/kazakhstan-launches-qazvac-its-own-covid-19-vaccine/ |website=EURACTIV |date=23 April 2021| name-list-style = vanc}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=3000
|description=Randomised, blind, placebo-controlled trial<ref name="QazCov3">{{#invoke:Cite web| |title=Immunogenicity, Efficacy and Safety of QazCovid-in COVID-19 Vaccine |url=https://clinicaltrials.gov/ct2/show/NCT04691908 |date=31 December 2020 |website=[[ClinicalTrials.gov]] |id=NCT04691908}}</ref>
|whenwhere=Mar 2021{{snd}}Jul 2021, Kazakhstan<ref name="QazCov3"/>}}
|
|{{CovidVacNum|QazCovid-in}}
|- valign="top"
|'''[[Minhai COVID-19 vaccine]]''' <small>(KCONVAC)</small><br />Minhai Biotechnology Co., [[Shenzhen Kangtai Biological Products]]
|China
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]] (vero cell)
|2 doses<br />4 weeks<wbr /><ref name="NCT04852705"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=28000|references=<ref name="NCT04852705">{{#invoke:Cite web| |title=A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04852705 |website=[[ClinicalTrials.gov]] |date=21 April 2021 |access-date=22 April 2021 |id=NCT04852705}}</ref>|description=Multi-national, Randomized, Double-blind, Placebo-controlled.
|whenwhere=April–Nov 2021, China, Malaysia, the Philippines
}}
|
|{{CovidVacNum|Minhai}}
|- valign="top"
|'''[[COVIran Barakat]]''' <small>(COVIRAN)</small><ref name=B>{{#invoke:Cite web| |url=https://www.aljazeera.com/news/2020/12/29/iran-covid-vaccine-trials-start|title=COVIran Barakat: Iran launches human trials of its COVID vaccine |website=aljazeera|date=29 December 2019|access-date=}}</ref><br />[[Barakat Pharmaceutical Group]], Shifa Pharmed Industrial Group
|Iran
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]]
|2 doses<br />4 weeks<wbr /><ref name="IRCT20201202049567N3"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=30500|description=Phase II-IIIa (20,000): Randomized, double-blind, parallel arms, placebo-controlled.<ref name="IRCT20201202049567N3">{{#invoke:Cite web| |title=A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years |url=https://en.irct.ir/trial/54881 |website=Iranian Registry of Clinical Trials |access-date=27 March 2021}}</ref> <br /> Phase IIIb (10,500)<ref>{{cite news |title=COVIRAN vaccine closer to completing human trials |url=https://www.tehrantimes.com/news/461725/COVIRAN-vaccine-closer-to-completing-human-trials |publisher=Theran Times |date=8 June 2021}}</ref>
|whenwhere=Mar–Jun 2021, Iran
}}
|
|{{CovidVacNum|COVIran Barakat}}
|- valign="top"
|'''[[Chinese Academy of Medical Sciences COVID-19 vaccine]]''' <small>(Covidful)</small><wbr /><ref name="NCT04412538">{{#invoke:Cite web| |title=Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04412538 |website=[[ClinicalTrials.gov]] |id=NCT04412538 |date=2 June 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084852/https://clinicaltrials.gov/ct2/show/NCT04412538/ }}</ref><ref name="NCT04659239">{{#invoke:Cite web| |title=The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04659239 |website=[[ClinicalTrials.gov]] |id=NCT04659239 |access-date=10 March 2021 }}</ref><br />[[Peking Union Medical College|Chinese Academy of Medical Sciences]], Institute of Medical Biology
|China
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS‑CoV‑2]]
|2 doses<br />2 weeks<wbr /><ref name="NCT04659239"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}
|{{ClinicalStudyInfo|align=left|phase=3|participants=34,020|description=Randomized, double-blinded, single-center, placebo-controlled
|whenwhere=Jan–Sep 2021, Brazil, Malaysia
}}
|
|{{CovidVacNum|Chinese Academy of Medical Sciences}}
|- valign="top"
|'''[[Soberana 02]]''' <small>(FINLAY-FR-2)</small><wbr /><br />[[BioCubaFarma]], Instituto Finlay de Vacunas
|Cuba
|[[Subunit vaccine|Subunit]] ([[Conjugate vaccine|conjugate]])
|2 doses<br />4 weeks<wbr /><ref name="RPCEC00000354"/>
| data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref name="soberana-abdala-storage-temperature"/>
|{{ClinicalStudyInfo|align=left|phase=3|participants=44,010|references=<ref>{{cite news | vauthors = Held S |title=Cuba's Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials |url=https://www.bioworld.com/articles/504357-cubas-soberana-02-sars-cov-2-vaccine-candidate-moves-to-phase-iii-trials |access-date=10 March 2021 |publisher=Bioworld |date=4 March 2021}}</ref><ref name="RPCEC00000354">{{#invoke:Cite web| |title=SOBERANA 02-FaseIII |url=https://rpcec.sld.cu/en/trials/RPCEC00000354-En |id=RPCEC00000354 |publisher=Registro Público Cubano de Ensayos Clínicos}}</ref>
|description=Multicenter, adaptive, parallel-group, randomized, placebo-controlled, double-blind
|whenwhere=Mar–May 2021, Cuba, Iran, Venezuela<ref>{{#invoke:Cite web||url=https://www.precisionvaccinations.com/vaccines/soberana-02-covid-19-vaccine |title=Cuba Soberana 02 COVID-19 Vaccine |date=8 June 2021 |website=precisionvaccinations.com |access-date=22 April 2021}}</ref>{{Unreliable source?|date=June 2021}}
}}
|
|{{CovidVacNum|Soberana 02}}
|- valign="top"
|'''[[MVC COVID-19 vaccine]]''' <small>(MVC-COV1901)</small><br />Medigen Vaccine Biologics, Dynavax Technologies<ref>{{cite news |title=Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate |url=https://www.globenewswire.com/news-release/2020/07/23/2066551/0/en/Dynavax-and-Medigen-Announce-Collaboration-to-Develop-a-Novel-Adjuvanted-COVID-19-Vaccine-Candidate.html |access-date=7 June 2021 |publisher=GlobeNewswire |date=23 July 2020}}</ref>
|Taiwan
||[[Subunit vaccine|Subunit]] (S-2P protein +CpG 1018)
|2 doses<br />4 weeks<wbr /><ref name="tfda20210802">{{cite web|url=https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637634910319587747&type=4|title=新冠肺炎(COVID-19)疫苗專家審查會議會議紀錄|publisher=TFDA|date=2 August 2021|language=zh-hant}}</ref>
|data-sort-value="5" |{{val|2|-|8|u=degC}}<wbr /><ref name="commonhealth">{{cite web|url=https://www.commonhealth.com.tw/article/84365|title=新冠疫苗6大廠牌比較：副作用、保護力、種類一次看懂|publisher=Common Health|date=2 June 2021|language=zh-hant|last=You|first=Yi-kai}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=5120 |references=<ref>{{#invoke:Cite web| |title=A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04695652 |website=[[ClinicalTrials.gov]] |date=5 January 2021 |id=NCT04695652 |access-date=11 March 2021 }}</ref><ref>{{#invoke:Cite web| |title=A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults |url=https://clinicaltrials.gov/ct2/show/NCT04822025 |website=[[ClinicalTrials.gov]] |date=30 March 2021 |id=NCT04822025 |access-date=3 April 2021 }}</ref><ref>{{cite news |author1=Shih-ching, Kao |title=Medigen begins making its vaccine |url=https://www.taipeitimes.com/News/biz/archives/2021/05/20/2003757696 |publisher=Taipei Times |date=20 May 2021}}</ref>
|description=Phase IIa (3,700): Prospective, double-blinded, multi-center, multi-regional.<br />Phase IIb (400): Prospective, randomized, double-blind, dose-comparison, multi-center.<br />Phase III (1,020): Parallel group, prospective, randomized, double-blind, active-controlled, two-arm, multi-center.<ref>{{#invoke:Cite web| |title=A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults |url=https://clinicaltrials.gov/ct2/show/study/NCT05011526 |website=[[ClinicalTrials.gov]] |date=18 August 2021 |id=NCT05011526 |access-date=18 August 2021 }}</ref>
|whenwhere=Dec 2020{{snd}}Dec 2021, Paraguay (phase III),<ref>{{cite news |title=COVID-19: Experts unsure about local vaccine and variants |url=https://www.taipeitimes.com/News/taiwan/archives/2021/08/08/2003762241 |access-date=13 August 2021 |publisher=Taipei Times |date=8 August 2021}}</ref> Taiwan (phase II), Vietnam (phase IIa)
}}
|
|{{CovidVacNum|Medigen}}
|- valign="top"
|'''[[ZyCoV-D]]'''<wbr /><ref name=":4">{{#invoke:Cite web| |website=ctri.nic.in|publisher=Clinical Trials Registry – India|title=A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects |id=CTRI/2020/07/026352 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|archive-url=https://web.archive.org/web/20201122022620/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|archive-date=22 November 2020|url-status=live|date=15 December 2020}}</ref><br />[[Cadila Healthcare]],<br />[[Biotechnology Industry Research Assistance Council]]
|India
|[[DNA vaccine|DNA]] ([[DNA plasmids|plasmid]] expressing [[SARS‑CoV‑2]] [[S protein]])
|
|
|{{ClinicalStudyInfo|align=left|phase=3|participants=28216|description=Randomised, blind, placebo-controlled trial<ref name="Zydus method"/>|references=<ref>{{cite news |title=Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine |url=https://www.thehindu.com/sci-tech/health/zydus-cadila-gets-dcgi-nod-to-initiate-phase-3-clinical-trials-for-covid-19-vaccine/article33486423.ece |work=The Hindu |date=3 January 2021 }}</ref><ref>{{#invoke:Cite web| |title=Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects. |url=http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=51254&EncHid=&userName=ZyCoV-D |website=ctri.nic.in |publisher=Clinical Trials Registry India |access-date=10 April 2021 }}</ref>
|whenwhere=Jan–May 2021, India<ref>{{cite press release |title=DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials |url=https://pib.gov.in/Pressreleaseshare.aspx?PRID=1685838 |publisher=[[Press Information Bureau]] |date=3 January 2021}}</ref>
}}
|
|{{CovidVacNum|ZyCoV-D}}
|}
{{notelist-la}}
 
== სქოლიო ==
მოძიებულია „https://ka.wikipedia.org/wiki/COVID-19-ის_ვაქცინა“-დან